Frag' FlorenceEvidenz. Klar. Anwendbar.
Uhr 7/8Sources Journal Tree
Easy Demo

Florence Themenbrowser · Onkologie · Seite 61

Was ist neu im Gesundheitswesen?

Entdecken Sie tatsächlich neu veröffentlichte Arbeiten aus Medizin, Pflege, Therapie, Public Health und Life Sciences. Sortiert nach Publikationsdatum, nicht nach Zitierhäufigkeit.

Themen erkunden

Aktuelle Forschung nach Fachgebiet

24 neue Nachweise auf dieser Seite Publiziert in den letzten 30 Tagen Neueste zuerst Crossref DOI
25.08.2026journal-article

Journal of Cancer Education

Cross-Cultural Validation of the 11-Item Frommelt Attitude Toward the Care of the Dying Scale Among U.S. Preclinical Medical Students

Marco Miniotti, Barbara Loera, Giorgia Molinengo, Michael Lee, Amy Hayton, Julio Silvestre, Paolo Leombruni

Abstract Positive attitudes toward caring for dying patients are core competencies in medical education and particularly relevant to cancer education, where physicians must be prepared for communication, symptom management, and end-of-life decision-making. The Frommelt Attitude Toward the Care of the Dying (FATCOD) scale is widely used to assess these attitudes, yet the original 30-item version has shown psychometric limitations across cultures. This study examined the factorial structure and measurement properties …

25.08.2026journal-article

AIDS

Reframing analytical treatment interruption through participants’ and decliners’ eyes: insights from an HIV remission trial

Sarah Lefebvre, Cécile Goujard, Laurence Meyer, Christine Durier, Mélanie Jaudon, Joséphine Tine, Lucie De Gastines, Nicolas Leturque, Vincent Meiffredy, Bruno Spire, Asier Saez-Cirion, Christel Protiere

Objectives: This study explored how participants and decliners perceived the French ANRS-175-RHIVIERA-01 trial, which evaluated HIV control during analytical treatment interruption (ATI) among individuals treated with antiretroviral treatment (ART) since acute HIV infection, virologically suppressed, and carrying the HLA-B35/53Bw4TTC2 genotype. It also explored how participants’ experiences evolved over follow-up. Methods: Between 2023 and 2024, semi-structured interviews were conducted with decliners and participa …

25.08.2026journal-article

Journal of Surgical Oncology

Multimodal Neoadjuvant Therapy for Pancreatic Ductal Adenocarcinoma (PDAC) With Vascular Involvement: What Is the Impact of Radiation on Perioperative Outcomes, Local Control, and Survival?

Dhruv J. Patel, Lauren M. Janczewski, Joseph H. Cotler, George Molina, Brett L. Ecker, David Bentrem, Shishir K. Maithel, Mohamed E. Abazeed, John P. Hayes, Bryan Palis, Amanda B. Francescatti, Ronald J. Weigel, Judy Boughey, Lesly Dossett, Akhil Chawla

ABSTRACT Objectives Neoadjuvant chemoradiation for PDAC with vascular invasion remains understudied. The aim of this study is to compare neoadjuvant chemotherapy with chemoradiation (NAC + CRT) versus neoadjuvant chemotherapy (NAC) for PDAC with vascular involvement. Methods The National Cancer Database was reviewed between 2018 and 2023, including patients with T4 PDAC initiating NAC or NAC + CRT. The primary outcome of overall survival (OS) was examined among unresected and resected cohorts. Secondary outcomes in …

25.08.2026journal-article

Discover Oncology

Exploratory analysis of a novel obesity-related gene-based prognostic model as a potential prognostic biomarker in multiple myeloma

Haoyuan Hong, Yingying Qin, Gengyang Lin, Meiwei Li, Qingyuan Xu, Houming Kan, Lei Jiang, Bin Luo

Abstract Background This study aimed to elucidate the genetic interplay between obesity and multiple myeloma (MM) and to develop a novel obesity-related gene-based prognostic model using an integrated multi-omics framework combining single-cell RNA sequencing (scRNA-seq) and bulk RNA sequencing (RNA-seq). Methods A differential expression analysis of the GSE132604 exploratory discovery cohort was performed using the limma package to identify obesity-related differentially expressed genes (DEGs). Weighted gene co-ex …

25.08.2026journal-article

The Oncologist

Ten-year survival of women with invasive breast cancer by stage, molecular subtype, and grade combined: a population-based study

Fabiola Giudici, Diego Serraino, Fabio Puglisi, Samuele Massarut, Lorenzo Gerratana, Serena Scomersi, Federica Toffolutti, Ettore Bidoli, Luigino Dal Maso, Friuli Venezia Giulia Cancer Registry working group, Tiziana Angelin, Emilia De Santis, Ornella Forgiarini, Elodie Lazzaretto, Mariella Losciale, Martina Taborelli

Abstract Background Stage at diagnosis, histologic grade, and molecular subtypes are established prognostic indicators for women with breast cancer (BC), but their impact on population-based survival estimates is poorly documented. This study assessed long-term BC survival trends according to these factors. Methods We identified women aged <75 years diagnosed with stage I-IV invasive BC between 2004 and 2014 from the Friuli Venezia Giulia (North Eastern Italy) Cancer Registry (N = 10,476). Follow-up through 2023 …

25.08.2026journal-article

International Journal of Molecular Sciences

Integrating Radiogenomics and CSF-Based Liquid Biopsy Sequencing for Precision Neuro-Oncology

Klaudia Kubiak, Edyta Szurowska

Glioblastoma and diffuse gliomas pose major therapeutic challenges due to marked intratumoral heterogeneity, limited tissue accessibility, and the blood–brain barrier. Tissue-based next-generation sequencing (NGS) remains essential for WHO CNS5 molecular classification, yet it is invasive and poorly suited to serial monitoring. Two complementary non- or minimally invasive approaches have advanced rapidly: radiogenomics, which correlates multiparametric MRI features with genomic alterations, and cerebrospinal fluid …

25.08.2026journal-article

Current Issues in Molecular Biology

ROMO1 and CD47 in Cervical Cancer: Parallel but Independently Regulated

Angel Yordanov, Stoyan Kostov, Polina Damyanova Dimitrova, Ihsan Hasan, Eva Tsoneva

Reactive Oxygen Species Modulator 1 (ROMO1) and CD47 have both been implicated in cervical carcinogenesis, but their relationship within the same tumor has not been investigated. We retrospectively analyzed immunohistochemical H-scores for ROMO1 and CD47 in 221 invasive cervical carcinomas, including 205 tumors with evaluable expression of both markers, and examined their associations with clinicopathological characteristics. ROMO1 and CD47 expression did not correlate at the individual-tumor level (Spearman ρ = −0 …

25.08.2026journal-article

International Journal of Molecular Sciences

Long Noncoding RNAs (lncRNAs) as Biomarkers of Prognosis in TNBC and Non-TNBC Breast Cancer Patients

Marcio Luis Acencio, Xinhui Wang, Flavia R. Rotea Mangone, Dirce Maria Carraro, Andrea S. Llera, Eliana S. F. W. Abdelhay, Nora Artagaveytia, Adrian Daneri-Navarro, Eduardo Moraes Reis, Leonardo Sanches, Roger Chammas, Osvaldo L. Podhajcer, Carlos Velazquez, Maria A. Nagai

Functional studies have shown that long noncoding RNAs (lncRNAs) play different roles in gene expression regulation, acting as epigenetic factors. Accumulating evidence indicates that lncRNAs modulate diverse biological processes, and their altered expression is associated with the development and progression of cancer, including BC. Here, aiming to identify lncRNAs associated with breast cancer, we performed a re-analysis of the expression data from 1071 tumors of eligible patients in the LACRN-MPBC Study. Using n …

25.08.2026journal-article

Substance Use & Addiction Journal

Distinguishing Medical From Nonmedical Cannabis Use Among US Young Adult Cancer Survivors

Carla J. Berg, Laura C. Schubel, Darcey M. McCready, Hermela Amdeta, Diane Ndisebuye, Cassidy R. LoParco, Hannah Arem

Background: Many young adults (YAs) who use cannabis use it both medically and nonmedically, which poses particular risks (eg, problematic use). Given the relevance of cannabis use among those with cancer, this qualitative study assessed YA cancer survivors’ experiences with and distinctions between medical and nonmedical use. Methods: From April to June 2025, we conducted qualitative interviews with 23 YA survivors (ages 18-39) reporting past-month cannabis use ( M age = 33.65 [SD = 5.99], 73.9% female, 73.9% Whit …

25.08.2026journal-article

Molecular Oncology

Unraveling the epigenetic code in cancer cell–tumor microenvironment crosstalk

Ji Hoon Park, Mi‐Young Kim

Epigenetics plays a central role in cancer development and progression by governing the expression of genes involved in these processes. Accumulating evidence strongly indicates that these mechanisms not only alter cancer cell‐intrinsic properties but also mediate reciprocal interactions between cancer cells and the tumor microenvironment (TME). In the context of cancer cell‐intrinsic changes, epigenetic alterations contribute to cancer cell plasticity by regulating stemness, cell state transitions, and therapy res …

25.08.2026journal-article

Journal of Bioinformatics and Computational Biology

Cell-cycle-interferon coordination changes across proliferative states in TNBC/basal-like breast cancer

Fatih Dikbas

Cohort-wide pathway correlations can hide strong relationships that differ across tumor states. We asked whether this occurs in TNBC/basal-like breast cancer by ordering tumors on prespecified Hallmark pathway axes and comparing pathway correlations in fixed low and high states under complete-family error control. The dominant result was a recurrent proliferation-interferon pattern: three independently replicated relationships showed weaker or reversed cell-cycle/interferon correlation at higher E2F or G2/M state. …

25.08.2026journal-article

npj Breast Cancer

A functional role for an intronic enhancer of ZBTB16 in AR-mediated tumour suppression in ER+ breast cancer

Maliha Wajahat, Dawn Gek Lian Thean, Richard Iggo, Anzu Okada, Zeyad D. Nassar, Wayne D. Tilley, Theresa E. Hickey, Amy R. Dwyer

Abstract The androgen receptor (AR) is a tumour suppressor in oestrogen receptor-positive (ER⁺) breast cancer, repressing cell cycle genes and restraining proliferation. We previously identified ZBTB16 as a candidate AR-regulated tumour-suppressor gene. Here, we validated ZBTB16 as a direct AR target and tested whether it mediates AR tumour-suppressor activity. In clinical cohorts, ZBTB16 mRNA expression was reduced in breast tumours relative to normal tissue, and higher expression correlated with improved survival …

25.08.2026journal-article

MedComm – Oncology

TRMT61A‐Mediated m1A Modification Suppresses FDX1 Translation to Drive Cuproptosis Evasion and Radioresistance in Hepatocellular Carcinoma

Yunyun Xiao, Yue Li, Zelei Li, Rui Wang, Dongni Shi, Yanling Wen, Yibing Pan, Chen Lin, Junguo Bu, Libing Song, Hui Dai

ABSTRACT Radioresistance remains a major obstacle to the curative treatment of hepatocellular carcinoma (HCC). While cuproptosis represents a potential strategy to eliminate resistant cells, the epitranscriptomic mechanisms underlying cuproptosis evasion remain unclear. Here, we identified tRNA methyltransferase 61 A (TRMT61A)‐mediated N1‐methyladenosine (m1A) modification as an important mediator of radioresistance by suppressing cuproptosis. m1A dot blot assays and immunohistochemical analyses revealed increased …

25.08.2026journal-article

Revista Ibero-Americana de Humanidades, Ciências e Educação

ABORDAGENS CLÍNICAS DAS PERFURAÇÕES GASTROINTESTINAIS: ATUALIZAÇÕES NO DIAGNÓSTICO E TRATAMENTO

João Vitor Ramos Lopes, Michelly Fernandes Freitas, Daniel Cardoso Pereira, Marilan Rossi, Isabel Andretto de Oliveira

As perfurações gastrointestinais constituem emergências cirúrgicas potencialmente fatais, caracterizadas pela ruptura da parede do trato gastrointestinal e consequente extravasamento de conteúdo para a cavidade peritoneal. Essa condição pode evoluir rapidamente para peritonite, sepse, choque e disfunção de múltiplos órgãos. Etiologias como doença ulcerosa péptica, diverticulite, neoplasias, isquemia, trauma e complicações iatrogênicas estão frequentemente envolvidas. Nesse contexto, avanços nos métodos diagnósticos …

25.08.2026journal-article

International Urology and Nephrology

LRRC8A as a candidate biomarker of cisplatin sensitivity in muscle-invasive bladder cancer: an exploratory immunohistochemical study

Michèle Alina Rytz, Saskia Hussung, Lorenz Frehner, Jörg Beyer, Laila Scheidewind, Beat Roth, Carmen Widmer, Aavash Baaral, Paola Francica, Mark A. Rubin, Sven Rottenberg, Antonio Rodriguez-Calero, Dilara Akhoundova

Abstract Background Despite recent therapeutic advances, platinum-based chemotherapy still remains a cornerstone in the treatment of muscle invasive bladder cancer (MIBC). We investigated the association between leucine-rich-repeat-containing 8A (LRRC8A) expression, a protein with a potential mechanistic role in platinum-sensitivity, and clinical outcomes following neoadjuvant chemotherapy in MIBC. Methods We histologically characterized transurethral resection of bladder tumor (TUR-B) and cystectomy MIBC samples. …

25.08.2026journal-article

JAMA

YEARS Algorithm for Diagnosis of Suspected Pulmonary Embolism in Patients With Cancer

Bram Akerboom, Emily S. L. Martens, Milou A. M. Stals, Rolf E. Brouwer, Michiel Coppens, Giorgio Costantino, Francis Couturaud, Yordi P. A. van Dooren, René van der Griend, Olivier Hugli, David Jiménez, Pieter W. Kamphuisen, Ouiam El Kharbouchi, Lucia J. M. Kroft, Jenneke Leentjens, Martje L. Maas, Thijs E. van Mens, Isabelle Mahé, Oene A. van Meer, Mattijs Out, Roberto Pola, Jo Raskin, Marc Righini, Reinier A. Sprenger, Fleur H. J. Kaptein, Rosa Talerico, Tobias Tritschler, Marije ten Wolde, Frederikus A. Klok, Menno V. Huisman, Hydra Study Investigators, Johanna M. Kwakkel, Therese S. Lapperre, Annemarie Hufkens, Wim Spysschaert, Iris N. Verhaegen, Dafne Balemans, Griet Vermeulen, Chloe C. Stessels, Gregoire Le Gal

Importance Although the YEARS algorithm is a safe and efficient way to rule out acute pulmonary embolism (PE), robust evidence on its accuracy in patients with cancer is lacking, and current guidelines suggest proceeding directly to computed tomographic pulmonary angiography (CTPA). Objective To compare the safety and efficiency of the YEARS algorithm with CTPA only to rule out acute PE in patients with active cancer. Design, Setting, and Participants The Hydra study was an open-label, randomized, investigator-init …

1 Zitationen
25.08.2026journal-article

Cancer

Vimseltinib for patients with tenosynovial giant cell tumor: A multicenter, open‐label, phase 2 trial

Silvia Stacchiotti, Jean‐Yves Blay, Piotr Rutkowski, Hans Gelderblom, Alejandro Falcón, Axel Le Cesne, Jayesh Desai, Emanuela Palmerini, César Serrano, Kristen N. Ganjoo, Gina Z. D’Amato, Christopher W. Ryan, Breelyn A. Wilky, Virginia Ferraresi, Ramy Saleh, Vinod Ravi, Albiruni Abdul Razak, Antonio Casado Herráez, Mahbubl Ahmed, Nicholas M. Bernthal, Michiel van de Sande, Mehdi Brahmi, Bartlomiej Szostakowski, Jasmine Sen, Nicholas A. Zeringo, Brooke Harrow, Supraja Narasimhan, Amanda Saunders, Maitreyi G. Sharma, Matthew L. Sherman, Andrew J. Wagner, William D. Tap

Abstract Background Tenosynovial giant cell tumor (TGCT) is a locally aggressive neoplasm caused by dysregulation of the colony‐stimulating factor 1 ( CSF1 ) gene. Patients report substantial pain, stiffness, and declining physical function; those whose disease is not amenable to surgery require systemic therapy. Vimseltinib is an oral, switch‐control kinase inhibitor of the CSF1 receptor (CSF1R). Here, the authors report safety and efficacy of vimseltinib in patients with TGCT based on prior treatment. Cohort A in …

25.08.2026journal-article

Statistics in Medicine

Nonparametric Assessment of the Calibration of Individualized Treatment Effects

Mohsen Sadatsafavi, Jeroen Hoogland, Thomas P. A. Debray, John Petkau

ABSTRACT An important aspect of the performance of algorithms that predict individualized treatment effects (ITEs) is moderate calibration, that is, the average treatment effect among individuals with predicted treatment effect of z being equal to z. The assessment of moderate calibration is a challenging task on two fronts: counterfactual responses are unobserved, and quantifying the conditional response function for models that generate continuous predicted values requires regularization. Perhaps because of these …

25.08.2026journal-article

Molecular Oncology

Arginine methylation as a regulatory ratchet in cancer: From substrate selection to malignant‐state stabilization

So Hyun Kwon, Ji Min Lee

Arginine methylation, catalyzed by the protein arginine methyltransferase (PRMT) family, is a widespread post‐translational modification yet its regulatory logic in cancer remains incompletely framed. Unlike rapidly reversible modifications, arginine methylation operates through a persistence‐prone, forward‐biased logic shaped by the lack of a broadly acting demethylase system, multisite substrates, and ongoing methylation flux. Here, we propose a regulatory ratchet framework in which PRMT‐dependent methylation can …

25.08.2026journal-article

BMC Psychiatry

Implementation and real-world effectiveness of a weighted blanket intervention and standard melatonin treatment for children with ADHD and sleep problems: protocol for a pragmatic longitudinal cohort study

Ingrid Larsson, Petra Svedberg, Håkan Jarbin, Jens Nygren, Annelie Lindholm, Katarina Aili, Julia S. Malmborg

Abstract Background Sleep problems are common in children with attention-deficit/hyperactivity disorder (ADHD), yet the real-world use, implementation, and long-term outcomes of weighted blankets and standard melatonin treatment remain understudied. This study protocol describes a research project evaluating the real-world effectiveness and implementation of a weighted blanket intervention and standard melatonin treatment for children with ADHD and sleep problems in routine clinical practice. The project focuses on …

25.08.2026journal-article

The British Journal of Psychiatry

Beyond control in psychiatric research: systematic review and meta-analysis of placebo treatment responses across major psychiatric conditions in citalopram and escitalopram RCTs

Masoud Ahmadzad-Asl, Roxana Jabbarinejad, Dorsa Shekouh, Reza Moshfeghinia, Mahdi Arshadi, Safoura Mohamadi, Saeedeh Shirdel, Farnoush Davoudi, Krista L. Lanctot, Stephanie H. Ameis, Ted J. Kaptchuk, Matthew J. Burke, Mark Sinyor

Background Placebos have historically been used as comparative tools in randomised controlled trials (RCTs), but their therapeutic effect, particularly in psychiatric conditions, warrant a more detailed exploration to improve research design and clinical practice. Aims This systematic review and meta-analysis examines the factors influencing placebo treatment effects across major psychiatric disorders, including depression, anxiety disorders, obsessive–compulsive disorder (OCD) and post-traumatic stress disorder (P …

25.08.2026journal-article

Journal of the American Psychiatric Nurses Association

Telemental Health Approaches for Rural Opioid Use Treatment: An Integrative Review

Jayme K. Weber, Roxanne K. Vandermause, Cynthia M. Schmidt

Background: Opioid use disorder (OUD) continues to disproportionately impact rural communities. Telemental health (TMH) offers a promising strategy to bridge this divide, especially in the context of expanding telehealth-delivered medication for OUD (tele-MOUD). Aim: The purpose of this review was to examine the current evidence on TMH approaches for treating OUD among rural adults. Methods: Databases including EMBASE, MEDLINE, CINAHL, PsycINFO, Scopus, the Cochrane Library, and ClinicalTrials.gov were searched in …

25.08.2026journal-article

Journal of Medical Genetics

Risk of breast cancer after ovarian cancer in germline BRCA1/2 heterozygotes

Robert D Morgan, Emma R Woodward, D Gareth Evans

Breast cancer risk after ovarian cancer in germline BRCA1/2 heterozygotes remains uncertain, with a recent large multicentre international study reporting lower-than-expected incidence in the first decade after ovarian cancer diagnosis (Apostol et al. 2026). We re‑evaluated our previously published regional cohort of 701 women with ovarian cancer and a germline BRCA1/2 pathogenic or likely pathogenic variant, restricting the analysis to those tested after ovarian cancer diagnosis and without prior breast cancer, to …

25.08.2026journal-article

PLOS One

Application of Cobas 6800 HPV testing and qPCR utilizing three genomically-optimized primer sets for detecting HPV DNA in the blood of HPV Positive dysplasia and cancer patients

Heba H. Mostafa, Amary Fall, Stéphanie Gaillard, Carole Fakhry, Zubair Khan, Tanguy Seiwert, Hao Wang, Hua-Ling Tsai, Amanda N. Fader, Charles A. Leath, Warner K. Huh, Rebecca C. Arend, Ya-chea Tsai, Joseph A. Califano, Deyin Xing, T.-C. Wu, Richard B. S. Roden

Use of quantitative polymerase chain reaction (qPCR) to measure viral DNA in plasma has promise for the detection and/or monitoring of high-risk human papillomavirus (hrHPV)-associated cancers. We examined Roche’s cobas 6800 HPV test for detection of hrHPV in plasma or peripheral blood mononuclear cells (PBMC) of patients with HPV-associated dysplasia or cancer. In our pilot study, this assay detected hrHPV DNA in 1 mL pre-treatment plasma of patients with advanced (stage II-IV) cervical cancer, but not stage I or …